311PDLeuprorelin (LEUP) combined with Letrozole (LET) with/without everolimus (EVE) in ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)

ConclusionsAdding EVE to LET demonstrated numerically improved PFS (D 4.3  Mo, median PFS), higher ORR. Significant improved PFS was noted in patients with visceral metastases.Clinical trial identificationNCT02344550.Legal entity responsible for the studySung-Bae Kim.FundingNovartis, Dongkook Pharma Co. Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research